NVCT · Nuvectis Pharma, Inc.

$24.49 +0.12 (+0.49%) At close · Sep 4

Russell 2000 member Rebalance outlook locked

Market Cap

$797.92M

32.58M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Net Income

-$26.44M -39.2%

FY2025

Diluted EPS

-$1.32 -18.9%

FY2025

Operating Cash Flow

-$16.01M -30.7%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021
Research & Development	+11.1%	—	—	$19.65M	$18.15M	$12.92M	$15.38M	$13.23M	$9.55M
General & Administrative	+16.2%	—	—	$9.22M	$9.42M	$6.93M	$7.52M	$6.01M	$3.35M
Operating Income	—	—	—	-$28.87M	-$27.57M	-$19.85M	-$22.9M	-$19.23M	-$12.89M
Net Income	—	—	—	-$27.85M	-$26.44M	-$19M	-$22.26M	-$19.09M	-$12.89M
Net Income Available to Common Stockholders	—	—	—	-$30.28M	-$28.87M	-$19M	-$22.26M	-$19.09M	-$12.89M
EPS (Basic) USD/shares	—	—	—	-$1.31	-$1.32	-$1.11	-$1.43	-$1.51	-$3.02
EPS (Diluted) USD/shares	—	—	—	-$1.31	-$1.32	-$1.11	-$1.43	-$1.51	-$3.02
Shares Outstanding (Basic Avg) shares	+19.9%	—	—	—	21.81M	17.11M	15.56M	12.66M	4.27M
Shares Outstanding (Diluted Avg) shares	+19.9%	—	—	—	21.81M	17.11M	15.56M	12.66M	4.27M

Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.

Debt data is being processed. Please check back later.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 7.26×

EV/EBIT

—

Peer median 11.84×

P/E (TTM)

—

Peer median 13.72×

Peer medians compare against the 303 similar-size Biotechnology companies (of 537 listed).

Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 58 filings 58 filers Visit website Investor relations